Acute leukemia, “inbound” but curable
One category of acute leukaemia is the type of blood doctor who loves and hates it – acute early and pyrocellular leukemia (acutepromylocytic leukemia, APL), which we often say is one of the types that can be cured if this type of leukaemia is diagnosed, since it can be cured in the long term at around 90 per cent. However, early diagnosis and timely and decisive treatment are particularly important when the onset of the disease is extremely dangerous and is marked by haemorrhage and condensation abnormalities, and when serious patients may die early as a result of brain and pulmonary haemorrhage.
Why is leukemia so easily bleeding? Acute early childhood leukemia is an abnormally stunted development of leukaemia cells at an early stage, with a marked increase in the number of early childhood cells in bone marrow and peripheral blood. And these abnormally early and young cytocellular cytocellular plasmas contain a large number of venomous particles, which contain substances that promote condensation and cause fibrous decomposition, which are released into blood during fibrosis of leukemia cells, which can lead to the continued occurrence of vascular condensation and, at the same time, to the continuous dissolation of these condensation blocks, which, in our profession, are referred to as abnormalities of internal condensation within the dispersive veins, which are extremely dangerous conditions, so it is important for the early prevention of haemorrhage and its importance.
What is the mechanism for acute early pyrocellular leukemia? The t (15; 17) (q22; q12) specific chromosomes are present in this type of leukaemia cell, resulting in the formation of a PML-RRAL alpha-integrated gene, whose protein products lead to cell fragmentation and failure. The question of how to block the appeal is therefore key to the treatment.
Acute early pyrocellular leukaemia (APL) was once a highly malignant blood disease, as treatment programmes were being optimized, and it gradually developed into the highest-pregnant acute leukaemia. Chinese haematologists have made a landmark contribution to APL treatment.
The chemotherapy programme for the early use of cythalcics combined (Ara-C) treated APLs, and 75% – 80% of APL patients were completely relieved. However, chemotherapy drugs tend to induce and exacerbate dispersive vascular coagulation (DIC) during the killing of leukaemia cells, resulting in severe bleeding and death. And the average time of relief for patients is shorter, with a DFS rate of only 35% to 45% in two years. In 1988, Wang Zhenjiang pioneered and achieved great success in the use of all-reverse viA acids (known as viA acids) for APL treatment, the emergence of which has revolutionized APL treatment. A combination of Via acid and chemotherapy can increase the CR rate to 90 per cent and the total survival (OS) rate to 80 per cent, but there are still 5-30 per cent relapses. In the 1970s, Professor Zhang Tin Tong and others used arsenic trioxide to treat leukaemia, especially APL. After more than a decade of exploration, blood specialists, such as Chen Shui-Chui, have used arsenic trioxide for treatment of both initial and recurrence APLs, with a CR rate of up to 90 per cent.
Since then, the joint arsenic trioxide programme of ViA acid has opened up the APL target for treatment and is now the main treatment programme for APL.
Therefore, as soon as acute early childhood leukemia is detected and diagnosed, immediate and prompt treatment is required, and the correct cognitive and scientifically sound treatment of the disease is an important building block for overcoming the disease and moving towards rehabilitation.
Author:
Yu-ting!
Ziru Hospital, Shandong University (Aoshima)
Part-time Social Work: Member of the Blood Section of the Shandong Society of Conversion Medicine, Third Blood Branch of the Central West Society of Medical Unions, Member of the Clinical Research Panel of the Aoshima Institute of Physiology
Main research directions: lymphoma, stem cell transplant
Leukemia acute early and pyrocellular leukemia,
